Experimental drug targets tough blood cancers in first human trial
NCT ID NCT04401020
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested an experimental drug called SAR442257 in 47 adults with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug might fight these cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SAR442257 (an experimental drug given by IV infusion)
What this could lead to
If successful, this could point toward a new treatment option for patients with hard-to-treat multiple myeloma or non-Hodgkin lymphoma.
What could go wrong
This is an early Phase 1 trial with only 47 participants, focused on safety and dosing. The drug may not shrink tumors or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM MALIGNANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Site Number : 8400001
Duarte, California, 91010, United States
-
Investigational Site Number : 2030001
Ostrava - Poruba, 70852, Czechia
-
Investigational Site Number : 2030002
Prague, 12808, Czechia
-
Investigational Site Number : 2030003
Brno, 62500, Czechia
-
Investigational Site Number : 4100001
Seoul, Seoul-teukbyeolsi, 03080, South Korea
-
Investigational Site Number : 4100002
Seoul, Seoul-teukbyeolsi, 06351, South Korea
-
Investigational Site Number : 5780001
Oslo, 0440, Norway
-
Investigational Site Number : 5780101
Oslo, 0450, Norway
-
Investigational Site Number : 7240001
Pamplona, Navarre, 31008, Spain
-
Investigational Site Number : 7240003
Badalona, Catalunya [Cataluña], 08916, Spain
-
Investigational Site Number : 7240004
Valencia, 46026, Spain
-
Investigational Site Number : 7240005
Santander, Cantabria, 39008, Spain
-
Investigational Site Number : 7240006
Madrid, Madrid, Comunidad de, 28027, Spain
-
Investigational Site Number : 7240007
Madrid, 28041, Spain
-
Mayo Clinic of Rochester Site Number : 8400003
Rochester, Minnesota, 55905, United States
-
University of Miami - Sylvester Comprehensive Cancer Center Site Number : 8400005
Miami, Florida, 33136, United States